About the Authors
National Institute for Health Research Oxford Biomedical Research Centre, John Radcliffe Hospital, Oxford, United Kingdom
Medical Research Council Clinical Trials Unit, London, United Kingdom
Nuffield Department of Clinical Laboratory Sciences, Oxford University, John Radcliffe Hospital, Oxford, United Kingdom
Department of Zoology, Oxford University, Oxford, United Kingdom
Nuffield Department of Clinical Medicine, Oxford University, John Radcliffe Hospital, Oxford, United Kingdom
Department of Microbiology, The General Infirmary, Old Medical School, Leeds, United Kingdom
Leeds Institute of Molecular Medicine, University of Leeds, Leeds, United Kingdom
The institution of DWC and TEAP received per-case funding from Optimer Pharmaceuticals to support fidaxomicin trial patient expenses. DWC and TEAP also received honoraria from Optimer Pharmaceuticals for participation in additional meetings related to investigative planning for fidaxomicin. MHW has received honoraria for consultancy work, financial support to attend meetings and research funding from bioMerieux, Optimer, Novacta, Pfizer, Summit, The Medicines Company, and Viropharma. All other authors have declared that no competing interests exist.
Conceived and designed the experiments: TEAP ASW DCW DWE MHW RMH. Performed the experiments: DHW LOC KED DG AV JF. Analyzed the data: DWE TEAP ASW. Wrote the first draft of the manuscript: TEAP DWE ASW DWC. Contributed to the writing of the manuscript: ASW DWE DHW KED RMH LOC DG AV JF MHW DCW TEAP. ICMJE criteria for authorship read and met: ASW DWE DHW KED RMH LOC DG AV JF MHW DCW TEAP. Agree with manuscript results and conclusions: ASW DWE DHW KED RMH LOC DG AV JF MHW DCW TEAP.